At Novo Nordisk we receive many different requests for information
to be used in the benchmarks etc. Instead of responding to each
request or questionnaire on an individual basis, we have decided to
make most of this information available online to ensure it serves a
wider audience. This information-upgrade of novonordisk.com will take
place during the first half of 2019.
We will continue responding to two benchmarks, as they have been assessed to be of particular importance to us. One is the Access to Medicine Index and the other is CDP.
Every other year, Novo Nordisk takes part in the extensive Access to Medicine Index (ATMI) ranking. Since 2008, the Access to Medicine Index has ranked pharmaceutical companies’ efforts to improve access to medicine in developing countries. The aim of the Index is to acknowledge and share best practices within the pharmaceutical industry.?
In 2018, Novo Nordisk was ranked tenth in the index; in 2016 we were ranked tenth; in 2014 we were ranked second; and in 2012 we were ranked sixth.
In 2018, we were awarded the performance score ‘A’ on the CDP
Climate A list - one of only three pharma companies globally. This is
the 16th time we submit information to the CDP report.
CDP is a not-for-profit organisation that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impacts.